Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Avexitide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amylyx Unveils Phase 3 LUCIDITY Trial For Avexitide In Hypoglycemia
    Amylyx Unveils Phase 3 LUCIDITY Trial For Avexitide In Hypoglycemia

    04 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241203046765/en

    BUSINESSWIRE
    04 Dec 2024
    Share Share
    Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results
    Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results

    08 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240808415481/en

    BUSINESSWIRE
    08 Aug 2024
    Share Share
    Amylyx Rebuilds Momentum Following Relyvrio Market Withdrawal
    Amylyx Rebuilds Momentum Following Relyvrio Market Withdrawal

    24 Jul 2024

    // BIOSPACE

    https://www.biospace.com/drug-development/amylyx-rebuilds-momentum-following-relyvrio-market-withdrawal

    BIOSPACE
    24 Jul 2024
    Share Share
    Amylyx Acquires Phase 3 GLP-1 Antagonist With FDA Breakthrough Status
    Amylyx Acquires Phase 3 GLP-1 Antagonist With FDA Breakthrough Status

    10 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240710172870/en

    BUSINESSWIRE
    10 Jul 2024
    Share Share
    Amylyx To Host Call On Avexitide Acquisition
    Amylyx To Host Call On Avexitide Acquisition

    09 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240709000861/en

    BUSINESSWIRE
    09 Jul 2024
    Share Share
    Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
    Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar

    22 Jun 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/amylyx-buy-bankrupt-eigers-experimental-drug-treat-low-blood-sugar-2024-06-21/

    REUTERS
    22 Jun 2024
    Share Share